Q-omics provides the consensus-scored C2orf74 profile across patient tissues and cancer cell-line models. C2orf74 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, C2orf74 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, C2orf74 RNA expression shows 18,584 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, COAD, and UVM as cancer lineages where C2orf74 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C2orf74 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C2orf74 survival associations across molecular data types. C2orf74 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C2orf74 RNA expression–survival associations across cancer types. High C2orf74 expression shows unfavorable associations in KICH, UVM, BRCA and SCLC, but favorable associations in MESO and SARC. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for C2orf74 RNA expression.
This table summarizes C2orf74 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for C2orf74. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C2orf74 shows lower tumor expression in COAD, KICH, BLCA, THCA, UCEC and BRCA. The COAD box plot shows higher C2orf74 RNA expression in normal versus tumor tissue (log2 FC = −0.861, t-test p < 0.001).
This table shows molecular features associated with C2orf74 in patient tissues and cancer cell lines. In patient samples, C2orf74 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, C2orf74 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE.
